Watch and Wait Approach for Re-excision After Unplanned Yet Macroscopically Complete Excision of Extremity and Superficial Truncal Soft Tissue Sarcoma is Safe and Does Not Affect Metastatic Risk or Amputation Rate.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 18 01 2019
pubmed: 25 7 2019
medline: 13 2 2020
entrez: 25 7 2019
Statut: ppublish

Résumé

The benefits of systematic re-excision (RE) after initial unplanned excision (UE) of soft tissue sarcoma (STS) are unknown. The aim of this study was to evaluate the impact of delayed RE versus systematic RE after UE on overall survival (OS), metastatic relapse-free survival (MRFS), local relapse-free survival (LRFS), and rate of amputation. Patients who underwent complete UE, without metastasis or residual disease, for primary extremity or superficial STS between 2007 and 2013 were analyzed. The amputation rate, LRFS, MRFS, and OS were assessed in cases of systematic RE in sarcoma referral centers (Group A), systematic RE outside of community centers (Group B), or without RE (Group C). Groups A, B, and C included 300 (48.2%), 71 (11.4%), and 251 (40.4%) patients, respectively. Median follow-up was 61 months and 5-year OS was 88.4%, 87.3%, and 88% in Groups A, B, and C, respectively (p = 0.22), while 5-year MFRS was 85.4%, 86.2%, and 84.9%, respectively (p = 0.938); RE (p = 0.55) did not influence MRFS. The 5-year LRFS was 83%, 73.5%, and 63.8% in Groups A, B and C, respectively (p = 0.00001). Of the 123 local recurrences observed, 0/28, 1/15, and 5/80 patients in Groups A, B, and C, respectively, required amputation (p = 0.41). Factors influencing LRFS were adjuvant radiotherapy [hazard ratio (HR) 0.21; p = 0.0001], initial R0 resection (HR 0.24, p = 0.0001), and Group A (HR 0.44; p = 0.01). Systematic RE in sarcoma centers offers best local control but does not impact OS. Delayed RE at the time of local relapse, if any, could be an option.

Sections du résumé

BACKGROUND BACKGROUND
The benefits of systematic re-excision (RE) after initial unplanned excision (UE) of soft tissue sarcoma (STS) are unknown.
OBJECTIVE OBJECTIVE
The aim of this study was to evaluate the impact of delayed RE versus systematic RE after UE on overall survival (OS), metastatic relapse-free survival (MRFS), local relapse-free survival (LRFS), and rate of amputation.
METHODS METHODS
Patients who underwent complete UE, without metastasis or residual disease, for primary extremity or superficial STS between 2007 and 2013 were analyzed. The amputation rate, LRFS, MRFS, and OS were assessed in cases of systematic RE in sarcoma referral centers (Group A), systematic RE outside of community centers (Group B), or without RE (Group C).
RESULTS RESULTS
Groups A, B, and C included 300 (48.2%), 71 (11.4%), and 251 (40.4%) patients, respectively. Median follow-up was 61 months and 5-year OS was 88.4%, 87.3%, and 88% in Groups A, B, and C, respectively (p = 0.22), while 5-year MFRS was 85.4%, 86.2%, and 84.9%, respectively (p = 0.938); RE (p = 0.55) did not influence MRFS. The 5-year LRFS was 83%, 73.5%, and 63.8% in Groups A, B and C, respectively (p = 0.00001). Of the 123 local recurrences observed, 0/28, 1/15, and 5/80 patients in Groups A, B, and C, respectively, required amputation (p = 0.41). Factors influencing LRFS were adjuvant radiotherapy [hazard ratio (HR) 0.21; p = 0.0001], initial R0 resection (HR 0.24, p = 0.0001), and Group A (HR 0.44; p = 0.01).
CONCLUSION CONCLUSIONS
Systematic RE in sarcoma centers offers best local control but does not impact OS. Delayed RE at the time of local relapse, if any, could be an option.

Identifiants

pubmed: 31338771
doi: 10.1245/s10434-019-07494-6
pii: 10.1245/s10434-019-07494-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3526-3534

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Gauthier Decanter (G)

Department of Medical Oncology, Oscar Lambret Center, Lille, France. g-decanter@o-lambret.fr.
General Oncology Department, Oscar Lambret Cancer Center, Lille, France. g-decanter@o-lambret.fr.

Eberhard Stoeckle (E)

Department of Surgery, Bergonie Institute, Bordeaux, France.

Charles Honore (C)

Department of Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Pierre Meeus (P)

Department of Surgical Oncology, Centre Léon Bérard, Lyon, France.

Jean Camille Mattei (JC)

Department of Orthopedic Surgery, Hôpital Nord, Marseille, France.

Pascale Dubray-Longeras (P)

Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.

Gwenael Ferron (G)

Department of Surgical Oncology, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.

Sébastien Carrere (S)

Department of Surgical Oncology, Montpellier Cancer Centre, Montpellier, France.

Sylvain Causeret (S)

Department of Surgery, Centre Georges François Leclerc, Dijon, France.

Jean-Marc Guilloit (JM)

Department of Medical Oncology, Regional Cancer Centre, Caen, France.

Magali Fau (M)

Department of Medical Surgery, Centre Alexis Vautrin, Vandœuvre-lès-Nancy, France.

Philippe Rosset (P)

Department of Orthopedic Surgery, University Hospital of Tours, Tours, France.

Jean-Christophe Machiavello (JC)

Breast Cancer and Reconstructive Surgery Unit, Centre Antoine Lacassagne, Nice, France.

Jean Baptiste Delhorme (JB)

Department of General and Digestive Surgery, Hautepierre Hospital, Strasbourg University Hospital, Strasbourg, France.

Nicolas Regenet (N)

Department of Digestive Surgery, Nantes Hospital, Nantes, France.

François Gouin (F)

Department of Orthopedic Surgery, Leon Berard Center, Lyon, France.

Jean-Yves Blay (JY)

Department of Medical Oncology, Leon Berard Center, Lyon, France.

Jean-Michel Coindre (JM)

Department of Pathology, Bergonié Cancer Institute, Bordeaux, France.

Nicolas Penel (N)

Medical Oncology Department, Centre Oscar Lambret and Lille University Hospital, Lille, France.

Sylvie Bonvalot (S)

Department of Medical Oncology and Surgery, Gustave Roussy Institute, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH